Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates
Open Access
- 16 March 2022
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (5-6) , 275-289
Abstract
The use of human adenoviruses (hAds) as oncolytic agents has demonstrated considerable potential. However, their efficacy in clinical studies is generally moderate and often varies between patients. This may, in part, be attributable to variable pre-existing neutralizing immunity in patients, which can impact the antitumor efficacy and lead to response heterogeneity. Our aim was to isolate new Ads for the development of oncolytic vectors with low prevalence of neutralizing immunity in the human population. To this end, we isolated a collection of new nonhuman primate (nhp) Ads from stool samples of four great ape species held captive. We elected 12 isolates comprising the broadest genetic variability for further characterization. For three new nhpAds, all classified as the human adenovirus B (HAdV-B) species, no neutralizing activity could be detected when exposed to a preparation of immunoglobulins isolated from a pool of >1,000 donors as a surrogate of population immunity. In addition, the nhpAds of the HAdV-B species showed enhanced oncolytic potency compared to nhpAds of the HAdV-C species as well as to human adenovirus type 5 (HAdV-C5) in vitro when tested in a panel of 29 human cancer cell lines. Next-generation sequencing of the viral genomes revealed higher sequence similarity between hAds and nhpAds of HAdV-B compared to HAdV-C, which might underlie the differences in oncolytic ability. As a proof-of-concept, the Rb-binding domain of the E1A protein of the gorilla-derived HAdV-B nhpAd-lumc007 was deleted, thereby creating a new oncolytic derivative, which demonstrated increased oncolytic potential compared to HAdV-C5. Collectively, our data demonstrate that nhpAds of the HAdV-B species can serve as an alternative for the development of potent oncolytic Ad vectors with limited pre-existing neutralizing immunity in humans.Keywords
This publication has 67 references indexed in Scilit:
- Molecular evolution of human adenovirusesScientific Reports, 2013
- Comparative Evaluation of Conventional and Real-Time PCR Assays for Detecting Bacteroides fragilis in Clinical SamplesJournal of Clinical Microbiology, 2013
- Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus MonkeysJournal of Virology, 2012
- Adenovirus Serotype 5 Neutralizing Antibodies Target both Hexon and Fiber following Vaccination and Natural InfectionJournal of Virology, 2012
- Toward an Integrated Human Adenovirus Designation System That Utilizes Molecular and Serological Data and Serves both Clinical and Fundamental VirologyJournal of Virology, 2011
- Using the Whole-Genome Sequence To Characterize and Name Human AdenovirusesJournal of Virology, 2011
- Isolation and Characterization of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human PrimatesPLOS Pathogens, 2009
- Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon CancerPLOS ONE, 2008
- BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in VivoThe American Journal of Pathology, 2007
- Studies on transformation of Escherichia coli with plasmidsJournal of Molecular Biology, 1983